STUDY DESIGN: Retrospective review. OBJECTIVE: To determine if adjuvant radiation therapy (RT) improves overall survival (OS) following surgical resection of chordomas. SUMMARY OF BACKGROUND DATA: The role of RT for the treatment of chordomas remains incompletely described. Previous studies have not found adjuvant RT to improve OS, but these studies did not group patients based on surgical margin status or radiation dose or modality. We used the National Cancer Database to investigate the role of RT in chordomas following surgical resection. METHODS: Patients were stratified based on surgical margin status (positive vs. negative). Utilizing the Kaplan-Meier method, OS was compared between treatment modalities (surgical resection alone, therapeutic RT alone, and surgical resection plus therapeutic RT). OS was subsequently compared between patients treated with palliative dose (<40 Gy), low dose (40-65 Gy), and high dose (>65 Gy) RT. Similarly, OS was compared between advanced RT modalities including proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), and external beam radiation therapy (EBRT). A multivariable model was used to determine adjusted variables predictive of mortality. RESULTS: One thousand four hundred seventy eight chordoma patients were identified; skull base (n = 567), sacral (n = 551), and mobile spine (n = 360). Surgical resection and therapeutic adjuvant RT improved 5-year survival in patients with positive surgical margins (82% vs. 71%, P = 0.03). No clear survival benefit was observed with the addition of adjuvant RT in patients with negative surgical margins. High dose RT was associated with improved OS compared with palliative and low dose RT (P < 0.001). Advanced RT techniques and SRS were associated with improved OS compared with EBRT. In the multivariate analysis high dose advanced RT (>65 Gy) was superior to EBRT. CONCLUSION: Patients with positive surgical margins benefit from adjuvant RT. Optimal OS is associated with adjuvant RT administered with advanced techniques and cumulative dose more than 65 Gy. LEVEL OF EVIDENCE: 4.
STUDY DESIGN: Retrospective review. OBJECTIVE: To determine if adjuvant radiation therapy (RT) improves overall survival (OS) following surgical resection of chordomas. SUMMARY OF BACKGROUND DATA: The role of RT for the treatment of chordomas remains incompletely described. Previous studies have not found adjuvant RT to improve OS, but these studies did not group patients based on surgical margin status or radiation dose or modality. We used the National Cancer Database to investigate the role of RT in chordomas following surgical resection. METHODS: Patients were stratified based on surgical margin status (positive vs. negative). Utilizing the Kaplan-Meier method, OS was compared between treatment modalities (surgical resection alone, therapeutic RT alone, and surgical resection plus therapeutic RT). OS was subsequently compared between patients treated with palliative dose (<40 Gy), low dose (40-65 Gy), and high dose (>65 Gy) RT. Similarly, OS was compared between advanced RT modalities including proton beam therapy (PBT) and intensity-modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS), and external beam radiation therapy (EBRT). A multivariable model was used to determine adjusted variables predictive of mortality. RESULTS: One thousand four hundred seventy eight chordoma patients were identified; skull base (n = 567), sacral (n = 551), and mobile spine (n = 360). Surgical resection and therapeutic adjuvant RT improved 5-year survival in patients with positive surgical margins (82% vs. 71%, P = 0.03). No clear survival benefit was observed with the addition of adjuvant RT in patients with negative surgical margins. High dose RT was associated with improved OS compared with palliative and low dose RT (P < 0.001). Advanced RT techniques and SRS were associated with improved OS compared with EBRT. In the multivariate analysis high dose advanced RT (>65 Gy) was superior to EBRT. CONCLUSION: Patients with positive surgical margins benefit from adjuvant RT. Optimal OS is associated with adjuvant RT administered with advanced techniques and cumulative dose more than 65 Gy. LEVEL OF EVIDENCE: 4.
Authors: Peyman Kabolizadeh; Yen-Lin Chen; Norbert Liebsch; Francis J Hornicek; Joseph H Schwab; Edwin Choy; Daniel I Rosenthal; Andrzej Niemierko; Thomas F DeLaney Journal: Int J Radiat Oncol Biol Phys Date: 2016-10-13 Impact factor: 7.038
Authors: Nicolas Dea; Charles G Fisher; Jeremy J Reynolds; Joseph H Schwab; Laurence D Rhines; Ziya L Gokaslan; Chetan Bettegowda; Arjun Sahgal; Áron Lazáry; Alessandro Luzzati; Stefano Boriani; Alessandro Gasbarrini; Ilya Laufer; Raphaële Charest-Morin; Feng Wei; William Teixeira; Niccole M Germscheid; Francis J Hornicek; Thomas F DeLaney; John H Shin Journal: J Neurosurg Spine Date: 2018-10-19
Authors: M Mima; Y Demizu; D Jin; N Hashimoto; M Takagi; K Terashima; O Fujii; Y Niwa; T Akagi; T Daimon; Y Hishikawa; M Abe; M Murakami; R Sasaki; N Fuwa Journal: Br J Radiol Date: 2013-11-28 Impact factor: 3.039
Authors: Silvia Stacchiotti; Paolo Giovanni Casali; Salvatore Lo Vullo; Luigi Mariani; Elena Palassini; Mario Mercuri; Marco Alberghini; Silvana Pilotti; Licciana Zanella; Alessandro Gronchi; Piero Picci Journal: Ann Surg Oncol Date: 2009-10-22 Impact factor: 5.344
Authors: Ronny L Rotondo; Wendy Folkert; Norbert J Liebsch; Yen-Lin E Chen; Frank X Pedlow; Joseph H Schwab; Andrew E Rosenberg; G Petur Nielsen; Jackie Szymonifka; Al E Ferreira; Francis J Hornicek; Thomas F DeLaney Journal: J Neurosurg Spine Date: 2015-09-04
Authors: Kurtis Young; Torbjoern Nielsen; Hannah Bulosan; Tyler J Thorne; Christian T Ogasawara; Andrew C Birkeland; Dennis M Tang; Arthur W Wu; Toby O Steele Journal: Laryngoscope Investig Otolaryngol Date: 2022-09-09